Eli Lilly and Company
Global pharmaceutical company running one of the broadest portfolios of AI drug-discovery collaborations, spanning biologics, small molecules, and protein design.
- Company type
- Global pharmaceutical company
- Headquarters
- Indianapolis, United States
- Website
- https://www.lilly.com
- Profile last verified
- 2026-07-29
AI Partnerships & Deployments
- 2026-04-28 — Strategic partnership with Profluent (Profluent). Eli Lilly announced a strategic partnership with Profluent, which applies AI to protein and genome-editor design, to develop AI-designed recombinases for genetic medicine. The deal was reported to be worth up to $2.25 billion. Disclosed: Up to $2.25B (per reporting). Source: Reuters (accessed 2026-07-29)
- 2026-01-12 — Biologics-discovery collaboration with Chai Discovery (Chai Discovery). Eli Lilly entered a collaboration with Chai Discovery to apply its frontier AI models to computer-aided design of biologics. Financial terms were not disclosed in the announcement. Source: BioSpace (Chai Discovery release) (accessed 2026-07-29)
- 2026-01-12 — NVIDIA AI Co-Innovation Lab (NVIDIA). Eli Lilly and NVIDIA announced an AI Co-Innovation Lab to apply accelerated computing and AI to drug discovery, including a physical facility in the Bay Area expected to open in March 2026. Lilly is investing over $1 billion over five years. Disclosed: Over $1B over five years. Source: NVIDIA newsroom (with Fierce Biotech coverage) (accessed 2026-07-29)
- 2025-08-14 — GPCR small-molecule collaboration with Superluminal Medicines (Superluminal Medicines). Eli Lilly partnered with Superluminal Medicines to advance AI-designed small-molecule therapeutics against GPCR targets for cardiometabolic disease and obesity. Superluminal is eligible to receive up to $1.3 billion including upfront and near-term payments, equity investment, and milestones. Disclosed: Up to $1.3B including upfront, equity, and milestones. Source: PR Newswire (Superluminal Medicines release) (accessed 2026-07-29)
- 2025-04-17 — AI-driven antibody-therapeutics collaboration with BigHat Biosciences (BigHat Biosciences). Eli Lilly and BigHat Biosciences agreed to collaborate on AI-driven design of antibody therapeutics, combining BigHat's machine-learning platform with laboratory automation. Financial terms were not disclosed. Source: Business Wire (BigHat Biosciences release) (accessed 2026-07-29)
- 2024-01-07 — Multi-target small-molecule collaboration with Isomorphic Labs (Isomorphic Labs). Eli Lilly entered a strategic multi-target research collaboration with Isomorphic Labs to apply its AI drug-design engine to the discovery of small-molecule therapeutics against undisclosed targets. Lilly paid $45 million upfront, with Isomorphic eligible for up to $1.7 billion in milestone payments (a total potential value of roughly $1.745 billion) plus royalties. Disclosed: $45M upfront; up to $1.7B in milestones (~$1.745B total), plus royalties. Source: PR Newswire (Isomorphic Labs release) (accessed 2026-07-29)
- 2021-07-08 — Neuroscience drug-discovery collaboration with Verge Genomics (Verge Genomics). Eli Lilly entered a three-year collaboration with Verge Genomics to apply its AI-driven, human-data-first platform to the discovery of novel targets and therapies in neuroscience, with Lilly able to select up to four targets. Verge received $25 million upfront (fee, equity, and near-term payments) and was eligible for up to $694 million in milestones (per reporting). Disclosed: $25M upfront (fee, equity, near-term payments); up to $694M in milestones (per reporting). Source: Fierce Biotech (accessed 2026-07-29)